Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/mEaUcBD2ZK